Travere Therapeutics (NASDAQ:TVTX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Travere Therapeutics (NASDAQ:TVTX) issued its quarterly earnings results on Tuesday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03, FiscalAI reports. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The company had revenue of $169.58 million for the quarter, compared to the consensus estimate of $157.27 million. During the same period in the previous year, the business posted $0.13 EPS. The company’s revenue for the quarter was up 48.2% on a year-over-year basis.

Here are the key takeaways from Travere Therapeutics’ conference call:

• Travere reported $169.6 million in Q2 revenue, including $141.1 million in FILSPARI sales, up approximately 96% year over year. FILSPARI generated more than 2,000 new patient start forms across IgA nephropathy and FSGS.
• The FSGS launch showed stronger-than-expected early uptake, with broad prescriber adoption, faster payer conversion, and shipments beginning within the first week after FDA approval. Management expects continued demand as new prescribers are activated and existing practices deepen their use, while cautioning that summer seasonality may create variability.
• IgA nephropathy demand continued to grow sequentially despite additional competitors entering the market. Management emphasized FILSPARI’s differentiated efficacy and its potential foundational role alongside immune-modulating therapies.
• Travere advanced its pipeline, with pegtibatinase’s Phase III HARMONY study continuing toward top-line results in the second half of 2027 and civorebrutinib added through a $112.5 million licensing payment. The company plans to open a U.S. IND for civorebrutinib and evaluate it across multiple immune-mediated kidney diseases.
• Gross-to-net discounts for FILSPARI are expected to increase modestly in the third and fourth quarters as FSGS utilization rises, although full-year discounts remain projected in the mid-20% range. Q2 other expense also included a $40 million inducement charge tied to convertible-note repurchases.

Travere Therapeutics Stock Up 1.9%

Shares of TVTX stock traded up $1.04 during trading on Tuesday, hitting $56.02. The company had a trading volume of 2,458,813 shares, compared to its average volume of 1,260,390. The stock’s 50-day moving average price is $53.77 and its 200 day moving average price is $40.46. Travere Therapeutics has a one year low of $15.60 and a one year high of $60.10. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 3.16.

Insider Activity at Travere Therapeutics

In related news, CEO Eric M. Dube sold 22,500 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $988,875.00. Following the sale, the chief executive officer owned 432,886 shares of the company’s stock, valued at $19,025,339.70. This trade represents a 4.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Timothy Coughlin sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $50.07, for a total transaction of $500,700.00. Following the sale, the director directly owned 56,250 shares in the company, valued at $2,816,437.50. The trade was a 15.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 42,460 shares of company stock worth $1,954,542 in the last three months. Insiders own 4.44% of the company’s stock.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in shares of Travere Therapeutics in the 2nd quarter worth about $33,000. State of Wyoming bought a new position in Travere Therapeutics in the 4th quarter worth approximately $37,000. Smartleaf Asset Management LLC increased its position in shares of Travere Therapeutics by 69.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after buying an additional 487 shares during the period. Headlands Technologies LLC purchased a new position in shares of Travere Therapeutics during the 2nd quarter valued at $73,000. Finally, Empowered Funds LLC bought a new position in Travere Therapeutics in the 4th quarter worth about $115,000.

Analyst Ratings Changes

Several research firms recently issued reports on TVTX. HC Wainwright increased their price target on shares of Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Citigroup increased their price objective on shares of Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 15th. Guggenheim upped their target price on shares of Travere Therapeutics from $56.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Weiss Ratings cut shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Finally, Wedbush lifted their price objective on shares of Travere Therapeutics from $55.00 to $61.00 and gave the company an “outperform” rating in a report on Monday, June 22nd. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.58.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.